阅读说明：本技术 一种低铅原料药盐酸艾司洛尔生产工艺 (Production process of low-lead bulk drug esmolol hydrochloride ) 是由 潘继成 臧月龙 沈佳 于 2020-12-25 设计创作，主要内容包括：本发明属于原料药合成技术领域,尤其涉及一种低铅原料药盐酸艾司洛尔的生产工艺。本发明通过用复合除铅剂与盐酸艾司洛尔接触的方式,达到去除大部分铅从而实现低铅的目的。本发明具有通过专用的除铅方式使产品达到了低铅的质量,满足药物制剂对活性成份低铅的质量要求。本发明另外一个显著的优点是该复合除铅剂对产品的酸碱度没有苛刻的要求,其可以在合适的产品自身PH值范围内也不会影响除铅的效果,从而避免了常规理化除铅往往需要产品在较低PH值下操作由此造成产品酸降解杂质升高的弊端。(The invention belongs to the technical field of raw material medicine synthesis, and particularly relates to a production process of low-lead raw material medicine esmolol hydrochloride. The invention achieves the aim of removing most of lead and realizing low lead by using a mode of contacting the composite lead removing agent and the esmolol hydrochloride. The invention can make the product reach the quality of low lead by a special lead removing way, and meet the quality requirement of the medicinal preparation on the low lead of the active ingredient. The composite lead removing agent has no strict requirement on the pH value of the product, and the lead removing effect can not be influenced in a proper pH value range of the product, so that the defect that the acid degradation impurities of the product are increased due to the fact that the product is required to be operated at a lower pH value in the conventional physical and chemical lead removing process is overcome.)

1. A production process of low-lead bulk drug esmolol hydrochloride is characterized by sequentially comprising the following steps:

s1, adding the esmolol hydrochloride crude product into a refining container filled with a mixed solvent, keeping stirring, heating to completely dissolve the solid, and adding the composite lead removing agent into the esmolol hydrochloride solution to obtain a mixed solution;

s2, performing solid-liquid separation operation on the mixed solution to remove the compound lead removing agent mixture, placing the filtrate in a crystallization container for cooling crystallization, and performing solid-liquid separation to remove the mother solution to obtain a solid, namely the esmolol hydrochloride wet product;

s3, placing the esmolol hydrochloride wet product in a drying oven, drying to obtain the finished product of the low-lead esmolol hydrochloride,

wherein, the lead content of the esmolol hydrochloride finished product can meet the requirement of the injection through detection.

2. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, characterized in that the material in S1 comprises the following components by weight: 1 part of esmolol hydrochloride crude product, 8-20 parts of mixed solvent and 0.01-1 part of composite lead removing agent.

3. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the mixed solvent in S1 comprises ethyl acetate, tetrahydrofuran, dimethylformamide, acetone, methanol and toluene; the composite lead removing agent comprises modified amino silica gel, a copolymer of fumaric acid and propylene sulfonic acid, a mercapto silica gel metal adsorbent and sodium alkyl phosphonate white carbon black.

4. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 3, which is characterized in that: the mixed solvent in S1 is ethyl acetate and methanol, or ethyl acetate, tetrahydrofuran and acetone, or dimethylformamide, methanol and toluene, or tetrahydrofuran, methanol and toluene.

5. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 3, which is characterized in that: the composite lead removing agent in S1 is a copolymer of modified amino silica gel, fumaric acid and propylene sulfonic acid, or a copolymer of modified amino silica gel, mercapto silica gel metal adsorbent and sodium alkyl phosphonate white carbon black, or mercapto silica gel metal adsorbent, fumaric acid and propylene sulfonic acid.

6. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 4, which is characterized in that: the weight ratio of the mixed solvent in S1 is ethyl acetate, methanol = 4: 1, or ethyl acetate, tetrahydrofuran, acetone =3:1:2, or dimethylformamide, methanol, toluene =3: 2:1, or tetrahydrofuran, methanol, toluene =2:1: 1.

7. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 5, which is characterized in that: the weight ratio of the composite lead removing agent in S1 is modified amino silica gel: ratio of fumaric acid to propylene sulfonic acid interpolymer = 8: 3, or modified amino silica gel: mercapto silica gel metal adsorbent: sodium alkyl phosphonate white carbon =3:1:0.5, or mercapto silica gel metal adsorbent: fumaric acid and propylene sulfonic acid interpolymer = 5: 2.

8. the production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the granularity of the composite lead removing agent in S1 is 60-200 mu m.

9. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the granularity of the composite lead removing agent in S1 is 100 mu m.

10. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: and (S1), heating to 40-50 ℃, and stirring for reaction for 1.0-1.5 h.

11. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the cooling temperature in S2 is 0-10 ℃, the stirring speed is 25-30 r/min, and the crystallization time is 2.0-3.0 h.

12. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: vacuum filtration is adopted in the two solid-liquid separation operations in S2, and the vacuum degree is more than-0.06 Mpa.

13. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the degree of vacuum of the esmolol hydrochloride wet product in the S3 is more than-0.08 Mpa when being dried.

14. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the temperature of the esmolol hydrochloride wet product in the S3 is 40-50 ℃ when the wet product is dried.

15. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the drying time of the esmolol hydrochloride wet product in the S3 is controlled to be 6.0-7.0 h.

16. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the lead content of the esmolol hydrochloride finished product is detected by an ICP-MS method.

17. The production process of esmolol hydrochloride as a low-lead bulk drug according to claim 1, which is characterized in that: the lead content of the esmolol hydrochloride finished product is 0.02-0.03 ppm.

Technical Field

The invention belongs to the technical field of raw material medicine synthesis, and particularly relates to a production process of low-lead raw material medicine esmolol hydrochloride.

Background

Esmolol hydrochloride with chemical name (+/-) -3- {4- [ 2-hydroxy-3- (1-methylethylamino) propoxy ] phenyl } methyl propionate hydrochloride is an aryloxypropylamine ultra-short-acting selective beta 1 receptor blocker, mainly inhibits a beta 1 receptor by competing catecholamine binding sites, and has the effects of slowing down rest and exercise heart rates, reducing blood pressure, reducing myocardial oxygen consumption and the like. The traditional Chinese medicine composition has the characteristics of quick response, high bioavailability, short half-life period, definite curative effect, low side effect and the like, is mainly clinically used for treating supraventricular arrhythmia and acute myocardial ischemia at present, and also has obvious curative effects on acute myocardial infarction, unstable angina, postoperative hypertension and other symptoms.

According to the requirements of ICH, the lead content safe for human bodies is 5 mug/day, and the lead content level of the current esmolol hydrochloride is basically about 0.5 ppm. Based on a daily maximum dose of 30.3g for a large infusion, the daily dose of light from esmolol hydrochloride per day is calculated to be 15ug, well above the 5 ug/day limit, which is not accompanied by lead from pharmaceutical excipients. Therefore, the lead content in the esmolol hydrochloride product needs to be greatly reduced, and the lead content is basically required to be controlled below 0.05 ppm.

The functional groups in the metallic lead and the esmolol hydrochloride are combined together in a chelating way, and the traditional removal methods mainly comprise methods such as distillation, extraction, activated carbon adsorption, recrystallization and the like, but the methods have the following defects: obvious yield loss, complex operation, time and energy consumption, and more importantly, the requirement of the pharmaceutical preparation on low lead content of API can not be met.

By consulting patents, the inventor finds that no patent report on the aspect exists at present, and the invention of the process for reducing the lead content in the esmolol hydrochloride product is urgent in order to meet the requirements of the preparation on the low-lead esmolol hydrochloride product and reduce the adverse reaction of a patient.

Disclosure of Invention

The invention aims to provide a production process of low-lead bulk drug esmolol hydrochloride, which can achieve the effect of removing most of lead by a mode of contacting a special composite lead-removing reagent with the esmolol hydrochloride. The composite lead remover is a multifunctional group modified composite remover which takes modified silica gel as a main material, has stronger coordination groups and stronger affinity with metallic lead compared with drug molecules, and has the advantages that the product achieves the quality of low lead through the special composite lead remover and meets the requirement of a pharmaceutical preparation on the quality of API low lead.

The technical scheme adopted by the invention for solving the problems is as follows: a production process of low-lead bulk drug esmolol hydrochloride sequentially comprises the following steps:

s1, adding the esmolol hydrochloride crude product into a refining container filled with a mixed solvent, keeping stirring, heating to completely dissolve the solid, and adding the composite lead removing agent into the esmolol hydrochloride solution to obtain a mixed solution;

s2, performing solid-liquid separation operation on the mixed solution to remove the compound lead removing agent mixture, placing the filtrate in a crystallization container for cooling crystallization, and performing solid-liquid separation to remove the mother solution to obtain a solid, namely the esmolol hydrochloride wet product;

s3, placing the esmolol hydrochloride wet product in a drying oven, drying to obtain the finished product of the low-lead esmolol hydrochloride,

wherein, the lead content of the esmolol hydrochloride finished product can meet the requirement of the injection through detection.

The further preferred technical scheme is that the material in the S1 comprises the following components in parts by weight: 1 part of esmolol hydrochloride crude product, 8-20 parts of mixed solvent and 0.01-1 part of composite lead removing agent.

In the invention, the above 3 components are all the feeding materials of the product, the refining container is a stainless steel kettle (material is 316L), the stirring paddle is in a frame type (material is 316L), the frequency conversion controller is provided for controlling the rotating speed, and a stainless steel reflux condenser (material is 316L) is arranged on the stainless steel kettle end socket so that the vaporized mixed solvent flows back into the kettle.

The further preferred technical scheme is as follows: the mixed solvent in S1 comprises ethyl acetate, tetrahydrofuran, dimethylformamide, acetone, methanol and toluene; the composite lead removing agent comprises modified amino silica gel, a copolymer of fumaric acid and propylene sulfonic acid, a mercapto silica gel metal adsorbent and sodium alkyl phosphonate white carbon black.

The further preferred technical scheme is as follows: the mixed solvent in S1 is ethyl acetate and methanol, or ethyl acetate, tetrahydrofuran and acetone, or dimethylformamide, methanol and toluene, or tetrahydrofuran, methanol and toluene.

The further preferred technical scheme is as follows: the composite lead removing agent in S1 is a copolymer of modified amino silica gel, fumaric acid and propylene sulfonic acid, or a copolymer of modified amino silica gel, mercapto silica gel metal adsorbent and sodium alkyl phosphonate white carbon black, or mercapto silica gel metal adsorbent, fumaric acid and propylene sulfonic acid.

The further preferred technical scheme is as follows: the weight ratio of the mixed solvent in S1 is ethyl acetate, methanol = 4: 1, or ethyl acetate, tetrahydrofuran, acetone =3:1:2, or dimethylformamide, methanol, toluene =3: 2:1, or tetrahydrofuran, methanol, toluene =2:1: 1.

The further preferred technical scheme is as follows: the weight ratio of the composite lead removing agent in S1 is modified amino silica gel: ratio of fumaric acid to propylene sulfonic acid interpolymer = 8: 3, or modified amino silica gel: mercapto silica gel metal adsorbent: sodium alkyl phosphonate white carbon =3:1:0.5, or mercapto silica gel metal adsorbent: fumaric acid and propylene sulfonic acid interpolymer = 5: 2.

the further preferred technical scheme is as follows: the granularity of the composite lead removing agent in S1 is 60-200 mu m.

The further preferred technical scheme is as follows: the granularity of the composite lead removing agent in S1 is 100 mu m.

The further preferred technical scheme is as follows: and (S1), heating to 40-50 ℃, and stirring for reaction for 1.0-1.5 h.

The further preferred technical scheme is as follows: the cooling temperature in S2 is 0-10 ℃, the stirring speed is 25-30 r/min, and the crystallization time is 2.0-3.0 h.

The further preferred technical scheme is as follows: vacuum filtration is adopted in the two solid-liquid separation operations in S2, and the vacuum degree is more than-0.06 Mpa.

The further preferred technical scheme is as follows: the degree of vacuum of the esmolol hydrochloride wet product in the S3 is more than-0.08 Mpa when being dried.

The further preferred technical scheme is as follows: the temperature of the esmolol hydrochloride wet product in the S3 is 40-50 ℃ when the wet product is dried.

The further preferred technical scheme is as follows: the drying time of the esmolol hydrochloride wet product in the S3 is controlled to be 6.0-7.0 h.

The further preferred technical scheme is as follows: the lead content of the esmolol hydrochloride finished product is detected by an ICP-MS method.

The further preferred technical scheme is as follows: the lead content of the esmolol hydrochloride finished product is 0.02-0.03 ppm.

In the invention, the lead content in the esmolol hydrochloride product is far less than the preparation standard and the prior art, which is the superiority of the compound lead remover used in the invention.

The invention achieves the purpose of reducing the content of heavy metal lead in the esmolol hydrochloride by using the mode that the composite lead removing agent adsorbs the element lead in the esmolol hydrochloride product under the dissolving action of the mixed solvent. The invention has the advantage that the content of heavy metal lead is lower than the standard requirement on the premise of ensuring that the product yield is not reduced.

Detailed Description

The following description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention.

Example 1

A production process of low-lead bulk drug esmolol hydrochloride sequentially comprises the following steps:

s1, adding the esmolol hydrochloride crude product into a refining container filled with a mixed solvent, keeping stirring, heating to completely dissolve the solid, and adding the composite lead removing agent into the esmolol hydrochloride solution to obtain a mixed solution;

s2, performing solid-liquid separation operation on the mixed solution to remove the compound lead removing agent mixture, placing the filtrate in a crystallization container for cooling crystallization, and performing solid-liquid separation to remove the mother solution to obtain a solid, namely the esmolol hydrochloride wet product;

s3, placing the esmolol hydrochloride wet product in a drying oven, drying to obtain the finished product of the low-lead esmolol hydrochloride,

wherein, the lead content of the esmolol hydrochloride finished product can meet the requirement of the injection through detection.

The material in S1 comprises the following components by weight: 1 part of esmolol hydrochloride crude product, 10 parts of mixed solvent and 0.2 part of composite lead removing agent.

The mixed solvent in S1 is ethyl acetate and methanol, and the weight ratio of ethyl acetate to methanol = 4: 1.

the composite lead removing agent in S1 is a copolymer of modified amino silica gel, fumaric acid and propylene sulfonic acid, and the weight ratio is that the modified amino silica gel: ratio of fumaric acid to propylene sulfonic acid interpolymer = 8: 3.

the granularity of the composite lead removing agent in S1 is 100 mu m.

In S1, the temperature is raised to 40 ℃, and the stirring reaction time is 1.0 h.

The cooling temperature in S2 is 3 ℃, the stirring speed is 25r/min, and the crystallization time is 2.0 h.

Vacuum filtration is adopted in the two solid-liquid separation operations in S2, and the vacuum degree is-0.07 Mpa.

The degree of vacuum of the esmolol hydrochloride wet product in the S3 is-0.09 Mpa when being dried.

The temperature of the esmolol hydrochloride wet product in S3 is 40 ℃ when being dried.

The drying time of the esmolol hydrochloride wet product in S3 is controlled at 6.0 h. The lead content of the esmolol hydrochloride finished product is detected by an ICP-MS method.

In this embodiment, the content of lead in the finally obtained esmolol hydrochloride product is 0.023ppm, which is far less than the preparation standard and the prior art, which is the advantage of using the composite lead remover in the present invention.

Example 2

A production process of low-lead bulk drug esmolol hydrochloride sequentially comprises the following steps:

s1, adding the esmolol hydrochloride crude product into a refining container filled with a mixed solvent, keeping stirring, heating to completely dissolve the solid, and adding the composite lead removing agent into the esmolol hydrochloride solution to obtain a mixed solution;

s2, performing solid-liquid separation operation on the mixed solution to remove the compound lead removing agent mixture, placing the filtrate in a crystallization container for cooling crystallization, and performing solid-liquid separation to remove the mother solution to obtain a solid, namely the esmolol hydrochloride wet product;

s3, placing the esmolol hydrochloride wet product in a drying oven, drying to obtain the finished product of the low-lead esmolol hydrochloride,

wherein, the lead content of the esmolol hydrochloride finished product can meet the requirement of the injection through detection.

The material in S1 comprises the following components by weight: 1 part of esmolol hydrochloride crude product, 15 parts of mixed solvent and 0.6 part of composite lead removing agent.

The mixed solvent in the S1 is ethyl acetate, tetrahydrofuran and acetone, and the weight ratio of the ethyl acetate, the tetrahydrofuran and the acetone is =3:1: 2.

The composite lead removing agent in S1 is modified amino silica gel, a mercapto silica gel metal adsorbent and sodium alkyl phosphonate white carbon black, and the weight ratio is that the modified amino silica gel: mercapto silica gel metal adsorbent: white carbon black of sodium alkyl phosphonate =3:1: 0.5.

The granularity of the composite lead removing agent in S1 is 160 mu m.

In S1, the temperature is raised to 45 ℃, and the stirring reaction time is 1.0 h.

The cooling temperature in S2 is 2 ℃, the stirring speed is 28r/min, and the crystallization time is 2.0 h.

Vacuum filtration is adopted in the two solid-liquid separation operations in S2, and the vacuum degree is-0.07 Mpa.

The degree of vacuum of the esmolol hydrochloride wet product in the S3 is-0.09 Mpa when being dried.

The temperature of esmolol hydrochloride wet product in S3 is 46 ℃ when being dried.

The drying time of the esmolol hydrochloride wet product in S3 is controlled to be 7.0 h. The lead content of the esmolol hydrochloride finished product is detected by an ICP-MS method.

In this embodiment, the content of lead in the finally obtained esmolol hydrochloride product is 0.03ppm, which is much smaller than the preparation standard and the prior art, and this is the advantage of using the composite lead remover in the present invention.

Example 3

A production process of low-lead bulk drug esmolol hydrochloride sequentially comprises the following steps:

s1, adding the esmolol hydrochloride crude product into a refining container filled with a mixed solvent, keeping stirring, heating to completely dissolve the solid, and adding the composite lead removing agent into the esmolol hydrochloride solution to obtain a mixed solution;

s2, performing solid-liquid separation operation on the mixed solution to remove the compound lead removing agent mixture, placing the filtrate in a crystallization container for cooling crystallization, and performing solid-liquid separation to remove the mother solution to obtain a solid, namely the esmolol hydrochloride wet product;

s3, placing the esmolol hydrochloride wet product in a drying oven, drying to obtain the finished product of the low-lead esmolol hydrochloride,

wherein, the lead content of the esmolol hydrochloride finished product can meet the requirement of the injection through detection.

The material in S1 comprises the following components by weight: 1 part of esmolol hydrochloride crude product, 20 parts of mixed solvent and 0.8 part of composite lead removing agent.

The mixed solvent in S1 is dimethylformamide, methanol and toluene, and the weight ratio of dimethylformamide, methanol and toluene =3: 2:1, or tetrahydrofuran, methanol, toluene =2:1: 1.

The composite lead removing agent in S1 is a mercapto silica gel metal adsorbent and a copolymer of fumaric acid and propylene sulfonic acid, and the weight ratio is that the mercapto silica gel metal adsorbent: fumaric acid and propylene sulfonic acid interpolymer = 5: 2.

the granularity of the composite lead removing agent in S1 is 110 mu m.

In S1, the temperature is raised to 50 ℃, and the stirring reaction time is 1.2 h.

The cooling temperature in S2 is 2 ℃, the stirring speed is 30r/min, and the crystallization time is 2.0 h.

Vacuum filtration is adopted in the two solid-liquid separation operations in S2, and the vacuum degree is-0.07 Mpa.

The degree of vacuum of the esmolol hydrochloride wet product in the S3 is-0.09 Mpa when being dried.

The temperature of the esmolol hydrochloride wet product in S3 is 50 ℃ when being dried.

The drying time of the esmolol hydrochloride wet product in S3 is controlled to be 7.0 h. The lead content of the esmolol hydrochloride finished product is detected by an ICP-MS method.

In this embodiment, the content of lead in the finally obtained esmolol hydrochloride product is 0.021ppm, which is far smaller than the preparation standard and the prior art, and this is the advantage of using the composite lead remover in the present invention.

While the embodiments of the present invention have been described in detail, the present invention is not limited to the above embodiments, and various modifications can be made within the knowledge of those skilled in the art without departing from the spirit of the present invention. These are non-inventive modifications, which are intended to be protected by patent laws within the scope of the claims appended hereto.